Publications by authors named "Maurice Zauderer"

Claim this Profile
P
Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases.
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, Maurice Zauderer

Expert Opin Investig Drugs· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Emily Greengard, Robin Williams, Branden Moriarity, Xiaowei Liu, Charles G Minard, Maurice Zauderer

Pediatr Blood Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, John E Leonard, Ernest S Smith, Maurice Zauderer

Nat Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of poxvirus display to select antibodies specific for complex membrane antigens.
Ernest S Smith, Leslie A Balch, Maria Scrivens, Shuying Shi, Wei Wang, Maurice Zauderer

MAbs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Vaccinia-based system for directed evolution of GPCRs in mammalian cells.
Christoph Klenk, Maria Scrivens, Anina Niederer, Shuying Shi, Loretta Mueller, Maurice Zauderer

Nat Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conclusions of the SIGNAL study in Huntington and implications for treatment of other slowly progressive neurodegenerative diseases.
Maurice Zauderer, Elizabeth Erin Evans

Clin Transl Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, John E Leonard, Ernest S Smith, Maurice Zauderer

Nat Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity.
Elizabeth E Evans, Vikas Mishra, Crystal Mallow, Elaine M Gersz, Leslie Balch, Maurice Zauderer

J Neuroinflammation· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A biological classification of Huntington's disease: the Integrated Staging System.
Sarah J Tabrizi, Scott Schobel, Emily C Gantman, Alexandra Mansbach, Beth Borowsky, Maurice Zauderer

Lancet Neurol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model.
Yilin Mao, Elizabeth E Evans, Vikas Mishra, Leslie Balch, Allison Eberhardt, Maurice Zauderer

Int J Mol Sci· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
Michael R Shafique, Terrence L Fisher, Elizabeth E Evans, John E Leonard, Desa Rae E Pastore, Maurice Zauderer

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Shalu Sharma Kharkwal, Christopher T Johndrow, Natacha Veerapen, Himanshu Kharkwal, Noemi A Saavedra-Avila, Maurice Zauderer

Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
Rupali Das, Peng Guan, Susan J Wiener, Nishant P Patel, Trevor G Gohl, Maurice Zauderer

Blood Adv· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Paul E Clavijo, Jay Friedman, Yvette Robbins, Ellen C Moore, Ernest Smith, Maurice Zauderer

Cancer Immunol Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Photoactivable Glycolipid Antigens Generate Stable Conjugates with CD1d for Invariant Natural Killer T Cell Activation.
Natacha Veerapen, Shalu Sharma Kharkwal, Peter Jervis, Veemal Bhowruth, Amareeta K Besra, Maurice Zauderer

Bioconjug Chem· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.
Christopher LaGanke, Lawrence Samkoff, Keith Edwards, Lily Jung Henson, Pavle Repovic, Maurice Zauderer

Neurol Neuroimmunol Neuroinflamm· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and preclinical characterization of an antibody specific for SEMA4D.
Terrence L Fisher, Christine A Reilly, Laurie A Winter, Tracy Pandina, Alan Jonason, Maurice Zauderer

MAbs· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials.
Terrence L Fisher, Jennifer Seils, Christine Reilly, Virginia Litwin, Lisa Green, Maurice Zauderer

Cytometry B Clin Cytom· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.
Amita Patnaik, Glen J Weiss, John E Leonard, Drew Warren Rasco, Jasgit C Sachdev, Maurice Zauderer

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D.
Elizabeth E Evans, Mark Paris, Ernest S Smith, Maurice Zauderer

Oncoimmunology· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
Elizabeth E Evans, Alan S Jonason, Holm Bussler, Sebold Torno, Janaki Veeraraghavan, Maurice Zauderer

Cancer Immunol Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody.
John E Leonard, Terrence L Fisher, Laurie A Winter, Chad A Cornelius, Christine Reilly, Maurice Zauderer

Mol Cancer Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.
Amber L Southwell, Sonia Franciosi, Erika B Villanueva, Yuanyun Xie, Laurie A Winter, Maurice Zauderer

Neurobiol Dis· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCL13 antibody for the treatment of autoimmune disorders.
Ekaterina Klimatcheva, Tracy Pandina, Christine Reilly, Sebold Torno, Holm Bussler, Maurice Zauderer

BMC Immunol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease.
Ernest S Smith, Alan Jonason, Christine Reilly, Janaki Veeraraghavan, Terrence Fisher, Maurice Zauderer

Neurobiol Dis· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis